Caffeine Pure Highly Concentrated

FDA's April 2018 Guidance for Industry establishes that dietary supplements containing pure or highly concentrated caffeine in dosage forms that require the consumer to measure are adulterated under FFDCA §402(f)(1)(A) — meaning they present a significant or unreasonable risk of illness or injury. The practical effect is to remove bulk powdered and concentrated liquid caffeine products from the direct-to-consumer market. Pre-measured dosage forms (capsules, tablets, gummies, RTD beverages) at typical per-serving caffeine levels (under approximately 200 mg) are not within the guidance's scope.

The guidance was triggered by a series of consumer deaths attributed to bulk caffeine products:

• 2014 — Logan Stiner (18, Ohio) and James Sweatt (24, Georgia) both died from caffeine overdose attributed to bulk powdered caffeine measured by spoon. Both products were sold direct-to-consumer in kilo-quantities of 99%+ pure caffeine.
• 2014–2015 — FDA issued Warning Letters to multiple bulk-powdered-caffeine sellers (Hard Rhino, SmartPowders, Bulk Powders, others) citing inability of consumers to safely measure a teaspoon containing 100x to 1000x the lethal dose.
• 2017 — Davis Cripe (16, South Carolina) died from caffeine-induced cardiac arrhythmia after consuming a McDonald's latte + Mountain Dew + Diet Mountain Dew within ~2 hours. Not bulk caffeine but contributed to broader regulatory attention.
• April 2018 — FDA issued the formal Guidance for Industry codifying the enforcement position.

The guidance establishes presumptive concentration thresholds below which a product is generally not within enforcement scope:

The thresholds are calibrated such that a consumer using a typical serving size (e.g. 1 teaspoon powder, 1 cup liquid) would receive at most ~30 mg caffeine — well below the safe single-serving threshold. Products above these thresholds are not automatically illegal but require justification (e.g. measured-dose packaging, child-resistant container, prominent warning).

For caffeine-containing supplements above approximate de-minimis thresholds, FDA expects (and reasonable-prudent industry practice provides):

• Per-serving caffeine quantity declared on Supplement Facts panel (mg per serving).
• Warning statement against consumption by children, pregnant or lactating women, people sensitive to caffeine, or with cardiovascular conditions.
• Maximum daily intake guidance (typically not exceeding 400 mg/day for healthy adults).
• Warning against combining with other caffeine sources.
• For pre-workout products with serving sizes 300+ mg: prominent overdose warning; warning against multiple servings.
• Child-resistant packaging recommended for high-per-serving products even when not technically required.

• Selling pure powdered caffeine direct-to-consumer (kilo bags, jugs, jars) — directly within enforcement scope; immediate Warning Letter risk.
• Selling concentrated liquid caffeine (1+ g/L) direct-to-consumer — same enforcement scope as powder.
• Mis-labelled per-serving caffeine in pre-workout — actual content significantly above label claim due to no overage control or analytical assay drift; consumer exceeds safe dose by following label.
• No warning on high-per-serving product — pre-workout at 350+ mg per serving without warning against multi-serving or sensitive-population consumption.
• Combination products without aggregate caffeine declaration — energy supplement contains caffeine + guarana + green tea extract + yerba mate; only synthetic caffeine declared; total caffeine load is 2-3x what label suggests.
• Variability across lots — caffeine assay drift between lots due to inadequate identity / potency testing; consumer expectation broken across re-purchase.
• B2B sale to formulator without B2B-only restriction — bulk caffeine sold via wholesale channel that retail consumer can access via online listing.

• Caffeine component flag: every caffeine-source component (synthetic anhydrous, guarana extract, green tea extract, yerba mate, kola nut, coffee bean, mate de coca, etc.) flagged with caffeine % content; aggregated automatically at BOM level for total per-serving caffeine.
• Per-serving caffeine ceiling: MMR-level configurable ceiling (e.g. 300 mg per-serving; 600 mg per-container). MMR approval blocked above ceiling without explicit medical-director sign-off.
• Bulk-form D2C block: SKU configured for D2C distribution + powder or liquid dosage form + caffeine concentration above 0.4% / 0.01% guidance thresholds → MMR approval blocked with explicit reference to 2018 guidance.
• Warning-statement enforcement: caffeine SKUs require warning-statement library entry attached to label; missing warning blocks label approval.
• Aggregate caffeine label declaration: V5 generates per-serving caffeine declaration line aggregating ALL caffeine-source components on Supplement Facts panel.
• Identity + potency testing: caffeine components require HPLC assay on every received lot (cannot be skipped via supplier-COA delegation); release blocked without valid assay.
• Lot-to-lot variability tracking: per-SKU caffeine assay trended across lots; >10% variability triggers process investigation.
• B2B-only flag: bulk caffeine SKUs flagged for B2B-only distribution; D2C channels (Amazon, brand website, retail SKU listings) blocked at order-entry.
• AE-reporting integration: caffeine-related serious AE (cardiac event, hospitalisation) auto-routes to DSNDCPA 15-day reporting workflow + medical-director review.